Search Results - "Gregoire, Jean C"

Effects of the P-Selectin Antagonist Inclacumab on Myocardial Damage After Percutaneous Coronary Intervention for Non―ST-Segment Elevation Myocardial Infarction: Results of the SELECT-ACS Trial by TARDIF, Jean-Claude, TANGUAY, Jean-François, COURNOYER, Daniel, JOHNSON, Dominique, MANN, Jessica, GUERTIN, Marie-Claude, L'ALLIER, Philippe L, WRIGHT, Scott S, DUCHATELLE, Valérie, PETRONI, Thibaut, GREGOIRE, Jean C, IBRAHIM, Reda, HEINONEN, Therese M, ROBB, Stephen, BERTRAND, Olivier F

“…The study aimed to evaluate inclacumab for the reduction of myocardial damage during a percutaneous coronary intervention (PCI) in patients with non-ST-segment…”
Get full text

Treatment With 5-Lipoxygenase Inhibitor VIA-2291 (Atreleuton) in Patients With Recent Acute Coronary Syndrome by TARDIF, Jean-Claude, L'ALLIER, Philippe L, TAUB, Rebecca, PRESSACCO, Josephine, IBRAHIM, Reda, GREGOIRE, Jean C, NOZZA, Anna, COSSETTE, Mariève, KOUZ, Simon, LAVOIE, Marc-André, PAQUIN, Janie, BROTZ, Tilmann M

“…Production of leukotrienes by 5-lipoxygenase (5-LO) has been linked to unstable atherosclerotic plaques and cardiovascular events. VIA-2291 is a potent 5-LO…”
Get full text

Pharmacogenomic Determinants of the Cardiovascular Effects of Dalcetrapib by Tardif, Jean-Claude, Rhéaume, Eric, Lemieux Perreault, Louis-Philippe, Grégoire, Jean C, Feroz Zada, Yassamin, Asselin, Géraldine, Provost, Sylvie, Barhdadi, Amina, Rhainds, David, L’Allier, Philippe L, Ibrahim, Reda, Upmanyu, Ruchi, Niesor, Eric J, Benghozi, Renée, Suchankova, Gabriela, Laghrissi-Thode, Fouzia, Guertin, Marie-Claude, Olsson, Anders G, Mongrain, Ian, Schwartz, Gregory G, Dubé, Marie-Pierre

“…BACKGROUND—Dalcetrapib did not improve clinical outcomes, despite increasing high-density lipoprotein cholesterol by 30%. These results differ from other…”
Get full text

Low-Dose Colchicine in Patients With Type 2 Diabetes and Recent Myocardial Infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT) by Roubille, François, Bouabdallaoui, Nadia, Kouz, Simon, Waters, David D, Diaz, Rafael, Maggioni, Aldo P, Pinto, Fausto J, Grégoire, Jean C, Gamra, Habib, Kiwan, Ghassan S, Berry, Colin, López-Sendón, José, Koenig, Wolfgang, Delorme, Laurent, Elbaz, Meyer, Coste, Pierre, Provencher, Mylène, Bassevitch, Zohar, Blondeau, Lucie, L'Allier, Philippe L, Guertin, Marie-Claude, Tardif, Jean-Claude

“…The cardiovascular benefits of low-dose colchicine have been demonstrated in patients with coronary disease. Its effects were evaluated in this prespecified…”
Get full text

Effect of treatment with 5‐lipoxygenase inhibitor VIA‐2291 (atreleuton) on coronary plaque progression: a serial CT angiography study by Matsumoto, Suguru, Ibrahim, Reda, Grégoire, Jean C., L'Allier, Philippe L., Pressacco, Josephine, Tardif, Jean‐Claude, Budoff, Matthew J.

“…Background Inflammation has a key role in the process of atherosclerosis. Production of leukotrienes by 5‐lipoxygenase has been linked to atherosclerotic…”
Get full text

The Benefits Conferred by Radial Access for Cardiac Catheterization Are Offset by a Paradoxical Increase in the Rate of Vascular Access Site Complications With Femoral Access: The Campeau Radial Paradox by Azzalini, Lorenzo, Tosin, Kunle, Chabot-Blanchet, Malorie, Avram, Robert, Ly, Hung Q, Gaudet, Benoit, Gallo, Richard, Doucet, Serge, Tanguay, Jean-François, Ibrahim, Réda, Grégoire, Jean C, Crépeau, Jacques, Bonan, Raoul, de Guise, Pierre, Nosair, Mohamed, Dorval, Jean-François, Gosselin, Gilbert, L'Allier, Philippe L, Guertin, Marie-Claude, Asgar, Anita W, Jolicœur, E Marc

“…The purpose of this study was to assess whether the benefits conferred by radial access (RA) at an individual level are offset by a proportionally greater…”
Get full text

Race and Ethnicity With Atherosclerotic Cardiovascular Disease Outcomes Within a Universal Health Care System: Insights From the CARTaGENE Study by d’Entremont, Marc-André, Ko, Dennis, Yan, Andrew T., Goodman, Shaun G., Ni, Jiayi, Poirier, Paul, Tardif, Jean-Claude, Grégoire, Jean C., Couture, Étienne L., Nguyen, Michel, Thanassoulis, George, Sharma, Abhinav, Huynh, Thao

“…It remains unclear whether racial and ethnic disparities for atherosclerotic cardiovascular disease (ASCVD) persist within universal health care systems. We…”
Get full text

Genotype-Dependent Effects of Dalcetrapib on Cholesterol Efflux and Inflammation: Concordance With Clinical Outcomes by Tardif, Jean-Claude, Rhainds, David, Brodeur, Mathieu, Feroz Zada, Yassamin, Fouodjio, René, Provost, Sylvie, Boulé, Marie, Alem, Sonia, Grégoire, Jean C, L’Allier, Philippe L, Ibrahim, Reda, Guertin, Marie-Claude, Mongrain, Ian, Olsson, Anders G, Schwartz, Gregory G, Rhéaume, Eric, Dubé, Marie-Pierre

“…BACKGROUND—Dalcetrapib effects on cardiovascular outcomes are determined by adenylate cyclase 9 gene polymorphisms. Our aim was to determine whether these…”
Get full text

Colchicine for Prevention of Atherothrombotic Events in Patients With Coronary Artery Disease: Review and Practical Approach for Clinicians by Marquis-Gravel, Guillaume, Goodman, Shaun G., Anderson, Todd J., Bell, Alan D., Bewick, David, Cox, Jafna, Grégoire, Jean C., Gupta, Anil, Huynh, Thao, Kertland, Heather, Kouz, Simon, L’Allier, Philippe L., Madan, Mina, Mancini, G. B. John, McPherson, Ruth, So, Derek Y.F., Welsh, Robert C., Wong, Graham, Tardif, Jean-Claude

“…A better understanding of the central role of inflammation in the development of coronary artery disease (CAD) has been the impetus for the evaluation of…”
Get full text

Clopidogrel 600-Mg Double Loading Dose Achieves Stronger Platelet Inhibition Than Conventional : Regimens Results From the PREPAIR Randomized Study by L'ALLIER, Philippe L, DUCROCQ, Grégory, LABARTHE, Benoit, THEROUX, Pierre, TARDIF, Jean-Claude, PRANNO, Nicolas, NOBLE, Stéphane, IBRAHIM, Reda, GREGOIRE, Jean C, AZZARI, Fabian, NOZZA, Anna, BERRY, Colin, DOUCET, Serge

“…The objective of this study was to compare the level of platelet inhibition achieved by 3 different clopidogrel loading regimens in patients undergoing…”
Get full text

Risk Stratification and Stroke Prevention Therapy Care Gaps in Canadian Atrial Fibrillation Patients (from the Co-ordinated National Network to Engage Physicians in the Care and Treatment of Patients With Atrial Fibrillation Chart Audit) by Patel, Ashish D., MD, Tan, Mary K., MSc, Angaran, Paul, MD, Bell, Alan D., MD, Berall, Murray, MD, Bucci, Claudia, PharmD, Demchuk, Andrew M., MD, Essebag, Vidal, MD, PhD, Goldin, Lianne, Green, Martin S., MD, Gregoire, Jean C., MD, Gross, Peter L., MD, Heilbron, Brett, MD, Lin, Peter J., MD, Ramanathan, Krishnan, MB, ChB, Skanes, Allan, MD, Wheeler, Bruce H., MD, Goodman, Shaun G., MD, MSc

“…The objectives of this national chart audit (January to June 2013) of 6,346 patients with atrial fibrillation (AF; ≥18 years without a significant heart valve…”
Get full text

Landscape of Lipid Management Following an Acute Coronary Syndrome Event: Survey of Canadian Specialists by Gouda, Pishoy, Welsh, Robert C., Padarath, Michelle, Grégoire, Jean C., Hegele, Robert A., Gupta, Milan

“…Following the occurrence of an acute coronary syndrome (ACS), patients are at high risk for subsequent cardiovascular events. Therapies to lower the level of…”
Get full text

Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction by Tardif, Jean-Claude, Kouz, Simon, Waters, David D, Bertrand, Olivier F, Diaz, Rafael, Maggioni, Aldo P, Pinto, Fausto J, Ibrahim, Reda, Gamra, Habib, Kiwan, Ghassan S, Berry, Colin, López-Sendón, José, Ostadal, Petr, Koenig, Wolfgang, Angoulvant, Denis, Grégoire, Jean C, Lavoie, Marc-André, Dubé, Marie-Pierre, Rhainds, David, Provencher, Mylène, Blondeau, Lucie, Orfanos, Andreas, L’Allier, Philippe L, Guertin, Marie-Claude, Roubille, François

“…Inflammation appears to play a role in atherosclerosis, raising the possibility that treatments that reduce inflammation could prevent cardiovascular events…”
Get full text

Time-to-treatment initiation of colchicine and cardiovascular outcomes after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT) by Bouabdallaoui, Nadia, Tardif, Jean-Claude, Waters, David D, Pinto, Fausto J, Maggioni, Aldo P, Diaz, Rafael, Berry, Colin, Koenig, Wolfgang, Lopez-Sendon, Jose, Gamra, Habib, Kiwan, Ghassan S, Blondeau, Lucie, Orfanos, Andreas, Ibrahim, Reda, Grégoire, Jean C, Dubé, Marie-Pierre, Samuel, Michelle, Morel, Olivier, Lim, Pascal, Bertrand, Olivier F, Kouz, Simon, Guertin, Marie-Claude, L’Allier, Philippe L, Roubille, Francois

“…Abstract Aims The COLchicine Cardiovascular Outcomes Trial (COLCOT) demonstrated the benefits of targeting inflammation after myocardial infarction (MI). We…”
Get full text

Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial by Tardif, Jean-Claude, Bouabdallaoui, Nadia, L'Allier, Philippe L, Gaudet, Daniel, Shah, Binita, Pillinger, Michael H, Lopez-Sendon, Jose, da Luz, Protasio, Verret, Lucie, Audet, Sylvia, Dupuis, Jocelyn, Denault, André, Pelletier, Martin, Tessier, Philippe A, Samson, Sarah, Fortin, Denis, Tardif, Jean-Daniel, Busseuil, David, Goulet, Elisabeth, Lacoste, Chantal, Dubois, Anick, Joshi, Avni Y, Waters, David D, Hsue, Priscilla, Lepor, Norman E, Lesage, Frédéric, Sainturet, Nicolas, Roy-Clavel, Eve, Bassevitch, Zohar, Orfanos, Andreas, Stamatescu, Gabriela, Grégoire, Jean C, Busque, Lambert, Lavallée, Christian, Hétu, Pierre-Olivier, Paquette, Jean-Sébastien, Deftereos, Spyridon G, Levesque, Sylvie, Cossette, Mariève, Nozza, Anna, Chabot-Blanchet, Malorie, Dubé, Marie-Pierre, Guertin, Marie-Claude, Boivin, Guy

“…Evidence suggests a role for excessive inflammation in COVID-19 complications. Colchicine is an oral anti-inflammatory medication beneficial in gout,…”
Get full text

Hypertension Canada's 2017 Guidelines for Diagnosis, Risk Assessment, Prevention, and Treatment of Hypertension in Adults by Leung, Alexander A., MD, MPH, Daskalopoulou, Stella S., MD, PhD, Dasgupta, Kaberi, MD, MSc, McBrien, Kerry, MD, MPH, Butalia, Sonia, BSc, MD, Zarnke, Kelly B., MD, MSc, Nerenberg, Kara, MD, MSc, Harris, Kevin C., MD, MHSc, Nakhla, Meranda, MD, MSc, Cloutier, Lyne, RN, PhD, Gelfer, Mark, MD, Lamarre-Cliche, Maxime, MD, Milot, Alain, MD, MSc, MD, Bolli, Peter, MD, Tremblay, Guy, MD, McLean, Donna, RN, NP, PhD, Tobe, Sheldon W., MD, MSc(HPTE), Ruzicka, Marcel, MD, PhD, Burns, Kevin D., MD, Vallée, Michel, MD, PhD, Prasad, G.V. Ramesh, MBBS, MSc, Gryn, Steven E., MD, Feldman, Ross D., MD, Selby, Peter, MBBS, MHSc, Pipe, Andrew, CM, MD, Schiffrin, Ernesto L., MD, PhD, McFarlane, Philip A., MD, PhD, Oh, Paul, MD, Hegele, Robert A., MD, Khara, Milan, MBChB, Wilson, Thomas W., MD, Penner, S. Brian, MD, Burgess, Ellen, MD, Sivapalan, Praveena, MD, Herman, Robert J., MD, Bacon, Simon L., PhD, Rabkin, Simon W., MD, Gilbert, Richard E., MD, PhD, Campbell, Tavis S., PhD, Grover, Steven, MD, MPA, Honos, George, MD, Lindsay, Patrice, RN, PhD, Hill, Michael D., MD, MSc, Coutts, Shelagh B., MD, Gubitz, Gord, MD, Campbell, Norman R.C., MD, Moe, Gordon W., MD, MSc, Howlett, Jonathan G., MD, Boulanger, Jean-Martin, MD, Prebtani, Ally, MD, Kline, Gregory, MD, Leiter, Lawrence A., MD, Jones, Charlotte, MD, PhD, Côté, Anne-Marie, MD, MHSc, Woo, Vincent, MD, Kaczorowski, Janusz, PhD, Trudeau, Luc, MD, Tsuyuki, Ross T., BSc (Pharm), PharmD, MSc, Hiremath, Swapnil, MD, MPH, Drouin, Denis, MD, Lavoie, Kim L., PhD, Hamet, Pavel, MD, PhD, Grégoire, Jean C., MD, Lewanczuk, Richard, MD, PhD, Dresser, George K., MD, PhD, Sharma, Mukul, MD, MSc, Reid, Debra, PhD, DtP, Lear, Scott A., PhD, Moullec, Gregory, PhD, Gupta, Milan, MD, Magee, Laura A., MD, MSc, Logan, Alexander G., MD, Dionne, Janis, MD, Fournier, Anne, MD, Benoit, Geneviève, MD, Feber, Janusz, MD, Poirier, Luc, BPharm, MSc, Padwal, Raj S., MD, MSc, Rabi, Doreen M., MD, MSc

“…Abstract Hypertension Canada provides annually updated, evidence-based guidelines for the diagnosis, assessment, prevention, and treatment of hypertension…”
Get full text

Pharmacogenetics-guided dalcetrapib therapy after an acute coronary syndrome: the dal-GenE trial by Tardif, Jean Claude, Pfeffer, Marc A, Kouz, Simon, Koenig, Wolfgang, Maggioni, Aldo P, McMurray, John J V, Mooser, Vincent, Waters, David D, Grégoire, Jean C, L’Allier, Philippe L, Wouter Jukema, J, White, Harvey D., Heinonen, Therese, Black, Donald M, Laghrissi-Thode, Fouzia, Levesque, Sylvie, Guertin, Marie Claude, Dubé, Marie Pierre

“…AIMSIn a retrospective analysis of dal-Outcomes, the effect of dalcetrapib on cardiovascular events was influenced by an adenylate cyclase type 9 (ADCY9) gene…”
Get full text

Simplified Canadian Definition for Familial Hypercholesterolemia by Ruel, Isabelle, Brisson, Diane, Aljenedil, Sumayah, Awan, Zuhier, Baass, Alexis, Bélanger, Alexandre, Bergeron, Jean, Bewick, David, Brophy, James M., Brunham, Liam R., Couture, Patrick, Dufour, Robert, Francis, Gordon A., Frohlich, Jiri, Gagné, Claude, Gaudet, Daniel, Grégoire, Jean C., Gupta, Milan, Hegele, Robert A., Mancini, G.B. John, McCrindle, Brian W., Pang, Jing, Raggi, Paolo, Tu, Jack V., Watts, Gerald F., Genest, Jacques

“…Familial hypercholesterolemia (FH) is an autosomal codominant lipoprotein disorder characterized by elevated low-density lipoprotein cholesterol (LDL-C) and…”
Get full text

Canadian Cardiovascular Harmonized National Guidelines Endeavour (C-CHANGE) guideline for the prevention and management of cardiovascular disease in primary care: 2018 update by Tobe, Sheldon W., MD MScCH, Stone, James A., MD PhD, Anderson, Todd, MD, Bacon, Simon, PhD, Cheng, Alice Y.Y., MD, Daskalopoulou, Stella S., MD PhD, Ezekowitz, Justin A., MBBCh MSc, Gregoire, Jean C., MD, Gubitz, Gord, MD, Jain, Rahul, MD MScCH, Keshavjee, Karim, MSc MD, Lindsay, Patty, RN PhD, L’Abbe, Mary, PhD, Lau, David C.W., MD PhD, Leiter, Lawrence A., MD, O’Meara, Eileen, MD, Pearson, Glen J., PharmD, Rabi, Doreen M., MD MSc, Sherifali, Diana, RN PhD, Selby, Peter, MBBS MHSc, Tu, Jack V., MD PhD, Wharton, Sean, MD PharmD, Walker, Kimberly M., MPH, Hua-Stewart, Diane, MPH, Liu, Peter P., MD

“…Tobe et al cite that the Canadian Cardiovascular Harmonized National Guideline Endeavor (C-CHANGE) is a nationally endorsed guideline process, targeting…”
Get full text

Evaluation and Management of Dyslipidemia in Patients Treated with Lorlatinib by Blais, Normand, Adam, Jean-Philippe, Nguyen, John, Grégoire, Jean C

“…The use of lorlatinib, an anaplastic lymphoma kinase (ALK) inhibitor for the treatment of -positive metastatic non-small cell lung cancer, is associated with…”
Get full text